UNSPSC 51314302: Acetaminophen/chlorpheniramine/dextromethorphan

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class RE509. This VA Drug Class (RE509) classifies this compound as belonging to the group ANTIHISTAMINE/ANTITUSSIVE/ANALGESIC.

The first component of this combination drug is an analgesic and antipyretic with the molecular formula C8H9NO2, a preparation that US FDA recognizes as an active ingredient or moiety under Unique Ingredient Identifier 362O9ITL9D, chemically known as n-(4-hydroxyphenyl)acetamide but more generally known as acetaminophen, which bears U.S. National Institutes of Health Compound Identifier 1983. Acetaminophen comes in many forms, including base, acetate, cysteine, cysteinylglycine, di-methyl derivative, glucuronide, glutathione, hemisuccinate, mercapturate, and sulfate.

UNSPSC 51314302 Acetaminophen/chlorpheniramine/dextromethorphan is a Commodity code that encompasses individual pharmaceutical products and combination over-the-counter and generic medications. Recent state and local activity under this code shows procurement of generic pharmaceuticals, OTC products, and emergency medical supplies (naloxone and drug deactivation systems) by county health departments, state health and human services agencies, and multistate cooperative purchasing alliances. Buying organizations source these products through established pharmaceutical wholesalers and direct manufacturer relationships, with contracts structured around competitive pricing, compliance with cGMP and Drug Supply Chain Security Act requirements, and quarterly or as-needed delivery schedules to healthcare and public health facilities.

Solicitation activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026 to procure 1,900 units of naloxone and 800 safe drug deactivation systems annually with a July 26, 2026 response deadline. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products to supply participating state and local government facilities across Minnesota and Oregon, with proposals due March 26, 2026 and contract effectiveness July 1, 2026. Vendors must maintain relationships with authorized wholesalers (AmerisourceBergen, Cardinal Health, Morris & Dickson), certify compliance with FDA and cGMP standards, carry substantial commercial general liability and network security insurance, and accept administrative fees and performance penalties tied to reporting, onboarding, and delivery compliance.